Holtway Global Hedge Pte. Ltd.
Pioneering Access to Tomorrow's Market Leaders in Space Technology and Beyond
SINGAPORE, SINGAPORE / ACCESSWIRE / August 26, 2024 / Holtway Global Hedge, a leading global wealth management firm with over €3 billion in assets under management, today reaffirms its commitment to providing clients with access to high-potential initial public offerings (IPOs). Should it become available, the firm is actively preparing its clients for anticipated opportunities in emerging and innovative sectors, including the highly speculated SpaceX IPO.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page."At Holtway Global Hedge, we understand the transformative power of groundbreaking companies entering the public market," said Kian Tan, CEO of Holtway Global Hedge. "We're dedicated to empowering our clients with opportunities to participate in the growth of these innovative ventures. Our expertise lies in identifying and evaluating high-potential IPOs across various sectors, and we're particularly excited about the prospects in the burgeoning space technology sector, exemplified by companies like SpaceX."
Holtway Global Hedge's deep understanding of global markets, coupled with its rigorous research and analysis, enables the firm to identify and evaluate IPOs, ensuring clients are prepared for these investment opportunities as they arise. They are mainly focused on companies at the forefront of innovation, such as SpaceX, which is revolutionizing space technology and satellite internet connectivity, offering significant growth potential for investors.
With a strong presence in Singapore and a global operations office in Canada, Holtway Global Hedge offers comprehensive wealth management and investment services to high-net-worth individuals and families across key markets in Asia, Europe, and North America. Their team of over 40 financial advisors and partners boasts a collective experience of over 250 years in wealth planning, investment management, and navigating complex global markets. This expertise allows them to provide personalized strategies tailored to each client's unique financial journey.
"We take a client-centric approach, ensuring that every investment strategy aligns with our clients' financial goals and risk tolerance," Tan added. "Our goal is to empower our clients to make informed decisions and build diversified portfolios that include access to exciting IPOs in sectors like space technology and other emerging industries."
About Holtway Global Hedge
Holtway Global Hedge is a trusted partner in global wealth management, providing strategic advice and comprehensive solutions to meet clients' diverse needs worldwide. Holtway Global Hedge empowers individuals and families to achieve their financial aspirations with a client-centric approach and a focus on long-term economic success.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.For further information on Holtway Global Hedge and its market insights, visit holtwayglobal.com or contact:
Media Contact:
Li Wei Tan
Director of Communications
Holtway Global Hedge
Email: media@holtwayglobal.com
Company Contact Information:
Holtway Global Hedge Pte. Ltd.
Phone: +65 3125 6069
Email: info@holtwayglobal.com
SOURCE: Holtway Global Hedge Pte. Ltd.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
GA-ASI Completes Full-Scale Fatigue Test on MQ-9B17.11.2025 03:10:00 CET | Press release
MQ-9B's Third Lifetime Test Completes the FSF Testing Process With a Total of 120,000 Hours DUBAI, UAE / ACCESS Newswire / November 16, 2025 / On October 31, 2025, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed its "third lifetime" of full-scale fatigue (FSF) testing for the MQ-9B Remotely Piloted Aircraft (RPA). Completion of FSF testing for the third and final lifetime includes a total of 120,000 operating hours (40,000+ flight hours per aircraft life) for the RPA and is a key milestone in validating the design of the airframe. The testing verifies the airframe structural integrity in support of certification to the NATO STANAG 4671 standard. The aim of the testing is to identify any potential structural deficiencies ahead of fleet usage and assist in developing inspection and maintenance schedules for the airframe. Test results will be used as documentation for certification and will form the basis for in-service inspections of structural components. "The completion o
GA-ASI and Saab Will Demonstrate AEW&C on MQ-9B in 202617.11.2025 03:05:00 CET | Press release
Two Aerospace Leaders Are Bringing Airborne Early Warning and Control to UAS DUBAI, UAE / ACCESS Newswire / November 16, 2025 / Following their announcement to bring Airborne Early Warning and Control (AEW&C) capability to the world's leading Remotely Piloted Aircraft (RPA) platform, General Atomics Aeronautical Systems, Inc. (GA-ASI) and Saab will now team up to demonstrate the capability in the summer of 2026. The demo will be conducted at GA-ASI's Desert Horizon flight operations facility in Southern California using a GA-ASI MQ-9B equipped with AEW&C supplied by Saab. In partnership with Saab, a leading company in AEW&C systems, GA-ASI is pairing Saab's AEW sensors with the world's longest-range, highest-endurance RPA, the MQ-9B. At sea or over land, adding AEW capabilities on MQ-9B enables persistent air surveillance and enables AEW in areas of the world where it doesn't currently exist or is unaffordable, such as for navy aircraft carriers at sea. "Adding AEW&C to the MQ-9B bring
Doha Tattoo Festival Announced as Ticket Sales Officially Open16.11.2025 12:45:00 CET | Press release
DOHA, QA / ACCESS Newswire / November 16, 2025 / Under the patronage of His Excellency Sheikh Khalifa bin Hamad bin Khalifa Al Thani, Minister of Interior and Commander of the Internal Security Force (Lekhwiya), the first edition of the Doha International Music and Marching Festival (Doha Tattoo) will be held from 16 to 20 December 2025 at Katara Cultural Village. A press conference held at Katara Cultural Village unveiled the line-up of participating bands and ticket details, attended by members of the Doha Tattoo organising committee and partner representatives. The Doha Tattoo will combine precision with musical artistry, showcasing performances by distinguished musical bands from seven countries: the United Kingdom, the United States of America, Turkia, Hashemite Kingdom of Jordan , the Sultanate of Oman, Kazakhstan, and the State of Qatar. The participating line-up includes the Irish Guards and the Royal Air Force Music Services from the United Kingdom, the United States Air Force
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom